The present invention discloses the application of cyathane diterpenoids in preparation of drugs for treating neuroinflammation. Seven cyathane diterpenoids 1-7 can significantly prevent LPS-induced BV-2 microglia from producing NO. The most active compound as 6 can reverse M1/M2 polarization of the microglia. 6 inhibits the pro-inflammatory proteins including iNOS and COX-2 through MAPK/NF-κB signaling pathways and promote the anti-inflammatory factors including IL-10 and ARG-1. An application prospect of the anti-inflammatory cyathane diterpenoids in the treatment of the neurodegenerative diseases is achieved.

The present invention discloses the application of cyathane diterpenoids in preparation of drugs for treating neuroinflammation. Seven cyathane diterpenoids 1-7 can significantly prevent LPS-induced BV-2 microglia from producing NO. The most active compound as 6 can reverse M1/M2 polarization of the microglia. 6 inhibits the pro-inflammatory proteins including iNOS and COX-2 through MAPK/NF-κB signaling pathways and promote the anti-inflammatory factors including IL-10 and ARG-1. An application prospect of the anti-inflammatory cyathane diterpenoids in the treatment of the neurodegenerative diseases is achieved.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.

The present invention discloses compound of Formula A represented by the structure Formula A

##STR00001##

The present invention discloses compound of Formula A represented by the structure Formula A

##STR00001##

The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I

##STR00001##

which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.